Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

abco health care pty ltd - 38447 - chair, examination/treatment, electric - these chairs are designed to provide an ergonomic response to patient examination and treatment. this is achieved through: ? permitting easy access for patients through minimum heights generally suitable for unaided wheelchair transfer; and ? easy adjustment of the couch to a height suitable for examination / treatment. adjustments to upholstery angles provide support for both patient and user during examination / treatment.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

abco health care pty ltd - 38457 - table, examination/treatment, - these products are intended to a. adjust the height and/or angle of the treatment surface by use of an electric actuator b. provide support / positioning of patients through adjustments to the upholstery sections c. move easily when required.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

helena laboratories australia pty ltd - ct945 - general laboratoryware ivds - the device(s) provide a quick and easy way to dispense blood into a test cassette without removing the cap from the collection tube or dispense a drop of blood onto test cards or point-of-care cassettes without removing the cap from the primary blood sample tube.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - flecainide acetate 100mg - tablet - 100 mg - active: flecainide acetate 100mg excipient: croscarmellose sodium hydrogenated vegetable oil magnesium stearate microcrystalline cellulose purified water starch

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - flecainide acetate 50mg - tablet - 50 mg - active: flecainide acetate 50mg excipient: croscarmellose sodium hydrogenated vegetable oil magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water

Nigérie - angličtina - NAFDAC (National Agency for Food and Drugs Administration and Control)

vit b1 - 1mg vit b2 1mg vit b6-0.5mgnicotinamide15mg

Nigérie - angličtina - NAFDAC (National Agency for Food and Drugs Administration and Control)

trimethoprim 40mg/5ml,sulphamethoxazole 200mg/5ml

Nigérie - angličtina - NAFDAC (National Agency for Food and Drugs Administration and Control)

vit b1 1.0mg, vit b6 0.5mg, vit b2 1.0mg, nicotinamide 15.0mg

Nigérie - angličtina - NAFDAC (National Agency for Food and Drugs Administration and Control)

trimethoprim 40mg /5ml sulphamethoxazole 200mg per 5ml

Spojené státy - angličtina - NLM (National Library of Medicine)

cephalon, inc. - trastuzumab (unii: p188anx8ck) (trastuzumab - unii:p188anx8ck) - herzuma is indicated for adjuvant treatment of her2 overexpressing node positive or node negative (er/pr negative or with one high risk feature [see clinical studies (14.1)] ) breast cancer - as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel - as part of a treatment regimen with docetaxel and carboplatin - as a single agent following multi-modality anthracycline based therapy. select patients for therapy based on an fda-approved companion diagnostic for a trastuzumab product [see dosage and administration (2.1)] . herzuma is indicated: - in combination with paclitaxel for first-line treatment of her2-overexpressing metastatic breast cancer - as a single agent for treatment of her2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. select patients for therapy based on an fda-approved companion diagnostic for a trastuzumab product [see dosage and administration (2.1)] . herzuma is indi